Natco Pharma receives USFDA EIR for Vizag facility

Andhra Pradesh: Natco Pharma Limited has announced the successful closure of inspection and receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India.

"The inspection conducted during the period from 24th March to 30th March 2020", Natco said in a filing

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Read also: Natco Pharma gets USFDA nod for Vizag Formulation Facility